Noradrenalină Amdipharm (Noradrenaline Tartrate)

Noradrenaline Tartrate, the active ingredient in Noradrenalină Amdipharm, is an adrenergic agonist presented as a sterile solution for intravenous use. It is employed to raise blood pressure in patients with acute hypotension, septic shock, or cardiac arrest. GNH USA supplies Noradrenalină Amdipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Noradrenalină Amdipharm is an adrenergic agonist used in critical‑care settings to manage severe circulatory failure. Acute hypotension: restores systemic vascular resistance and improves blood pressure. Septic shock: supports hemodynamics when endogenous catecholamine response is insufficient. Cardiac arrest: provides vasoconstrictive support during resuscitation efforts.

Noradrenalină Amdipharm may produce a range of adverse reactions that clinicians monitor during infusion.

Common Side Effects: - Tachycardia - Hypertension - Headache - Nausea - Anxiety - Arrhythmia

Serious or Rare Side Effects: - Myocardial ischemia - Severe hypertension leading to vascular injury - Tissue necrosis at the infusion site - Life‑threatening arrhythmias - Peripheral ischemia - Anaphylactic reaction

Use of Noradrenalină Amdipharm requires careful monitoring and adherence to safety guidelines. - Blood pressure monitoring: adjust infusion rate to maintain target MAP. - Cardiac monitoring: continuous ECG to detect arrhythmias. - Coronary disease caution: avoid excessive vasoconstriction in patients with ischemic heart disease. - Bolus avoidance: administer only as a controlled infusion, never as a rapid bolus. - Compatibility check: ensure diluent and line are compatible before administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Noradrenalină Amdipharm can interact with several drug classes, influencing cardiovascular response.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: additive vasoconstrictive effect. - Ergot alkaloids: severe peripheral ischemia.

Moderate Interactions (Monitor Closely): - Vasodilators (e.g., nitroglycerin): may require higher norepinephrine doses. - ACE inhibitors: potential for exaggerated hypotension. - Calcium channel blockers: may affect heart rate and contractility. - Diuretics: influence intravascular volume and response. - Anesthetic agents: may blunt pressor response.